ZA959367B - Melt-extrusion multiparticulates - Google Patents

Melt-extrusion multiparticulates

Info

Publication number
ZA959367B
ZA959367B ZA959367A ZA959367A ZA959367B ZA 959367 B ZA959367 B ZA 959367B ZA 959367 A ZA959367 A ZA 959367A ZA 959367 A ZA959367 A ZA 959367A ZA 959367 B ZA959367 B ZA 959367B
Authority
ZA
South Africa
Prior art keywords
melt
multiparticulates
extrusion multiparticulates
matrix
dispersed
Prior art date
Application number
ZA959367A
Other languages
English (en)
Inventor
Benjamin Oshlack
Mark Chasin
Hau-Pin Huang
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23306123&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA959367(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of ZA959367B publication Critical patent/ZA959367B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29B—PREPARATION OR PRETREATMENT OF THE MATERIAL TO BE SHAPED; MAKING GRANULES OR PREFORMS; RECOVERY OF PLASTICS OR OTHER CONSTITUENTS OF WASTE MATERIAL CONTAINING PLASTICS
    • B29B9/00—Making granules
    • B29B9/02—Making granules by dividing preformed material
    • B29B9/06—Making granules by dividing preformed material in the form of filamentary material, e.g. combined with extrusion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Mechanical Engineering (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Extrusion Moulding Of Plastics Or The Like (AREA)
  • General Preparation And Processing Of Foods (AREA)
ZA959367A 1994-11-04 1995-11-06 Melt-extrusion multiparticulates ZA959367B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/334,209 US5965161A (en) 1994-11-04 1994-11-04 Extruded multi-particulates

Publications (1)

Publication Number Publication Date
ZA959367B true ZA959367B (en) 1996-06-13

Family

ID=23306123

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA959367A ZA959367B (en) 1994-11-04 1995-11-06 Melt-extrusion multiparticulates

Country Status (17)

Country Link
US (11) US5965161A (fr)
EP (7) EP2283816A1 (fr)
JP (1) JP3186064B2 (fr)
KR (1) KR100232945B1 (fr)
AT (5) ATE452627T1 (fr)
AU (1) AU705894B2 (fr)
CA (1) CA2204180C (fr)
DE (5) DE69535426T2 (fr)
DK (5) DK0785775T4 (fr)
ES (5) ES2214512T3 (fr)
HK (3) HK1059887A1 (fr)
HU (1) HUT77626A (fr)
IL (5) IL142413A (fr)
PT (5) PT1741426E (fr)
TW (1) TW425288B (fr)
WO (1) WO1996014058A1 (fr)
ZA (1) ZA959367B (fr)

Families Citing this family (332)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US20080075781A1 (en) * 1992-11-25 2008-03-27 Purdue Pharma Lp Controlled release oxycodone compositions
IL109460A (en) 1993-05-10 1998-03-10 Euro Celtique Sa Controlled release formulation comprising tramadol
US20070275062A1 (en) * 1993-06-18 2007-11-29 Benjamin Oshlack Controlled release oxycodone compositions
US5914131A (en) * 1994-07-07 1999-06-22 Alza Corporation Hydromorphone therapy
GB9422154D0 (en) 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US20020006438A1 (en) * 1998-09-25 2002-01-17 Benjamin Oshlack Sustained release hydromorphone formulations exhibiting bimodal characteristics
DE19531277A1 (de) * 1995-08-25 1997-02-27 Basf Ag Verwendung von Lipiden als Hilfsmittel bei der Herstellung von festen Arzneiformen nach dem Schmelzextrusionsverfahren
GB9519363D0 (en) 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
DE19539360A1 (de) * 1995-10-23 1997-04-24 Basf Ag Verfahren zur Herstellung von festen Arzneiformen
GB9614902D0 (en) * 1996-07-16 1996-09-04 Rhodes John Sustained release composition
JPH1050306A (ja) * 1996-07-31 1998-02-20 Toyota Autom Loom Works Ltd 水素吸蔵合金電極の製造方法
PL191399B1 (pl) * 1996-10-28 2006-05-31 Gen Mills Inc Sposób kapsułkowania lub osadzania składnika w osnowie w procesie ciągłym, sposób kapsułkowania i/lub osadzania składników w osnowie opartej na węglowodanach, sposób kapsułkowania i/lub osadzania składników w osnowie oraz kapsułka
EP1342548B1 (fr) * 1996-10-28 2015-12-23 General Mills, Inc. Inclusion et encapsulation de particules à libération contrôlée et produit encapsulé
BE1010803A3 (fr) * 1996-12-16 1999-02-02 Therabel Research Sa Comprimes pharmaceutiques a liberation prolongee a base de tramadol et leur preparation.
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
WO1999001111A1 (fr) 1997-07-02 1999-01-14 Euro-Celtique, S.A. Formulations de tramadol stabilisees a liberation prolongee
DE19733505A1 (de) * 1997-08-01 1999-02-04 Knoll Ag Schnell wirksames Analgeticum
RS49982B (sr) * 1997-09-17 2008-09-29 Euro-Celtique S.A., Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
US6274591B1 (en) * 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
US6559158B1 (en) * 1997-11-03 2003-05-06 Ur Labs, Inc. Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
WO1999032120A1 (fr) * 1997-12-22 1999-07-01 Euro-Celtique, S.A. Procede prevenant l'abus des doses orales d'opioides
PT2266564E (pt) 1997-12-22 2013-06-20 Euro Celtique Sa Forma de dosagem farmacêutica por via oral compreendendo uma combinação de um agonista opióide e de um antagonista opióide
US8524277B2 (en) 1998-03-06 2013-09-03 Alza Corporation Extended release dosage form
US6074689A (en) * 1998-03-10 2000-06-13 Immucell Corporation Colonic delivery of protein or peptide compositions
ATE438305T1 (de) 1998-03-23 2009-08-15 Gen Mills Inc Verkapselung von komponenten in essbaren produkten
AR018321A1 (es) * 1998-03-26 2001-11-14 Alza Corp Una forma de dosificacion de liberacion prolongada que comprende oxibutinina y los usos de la oxibutinina y de la forma de dosificacion de liberacionprolongada.
SA99191255B1 (ar) 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
DE19859636A1 (de) * 1998-12-23 2000-06-29 Hexal Ag Kontrolliert freisetzende pharmazeutische Zusammensetzung mit Tilidinmesylat als Wirkstoff
US7429407B2 (en) * 1998-12-30 2008-09-30 Aeromatic Fielder Ag Process for coating small bodies, including tablets
EP1140033B1 (fr) * 1999-01-14 2005-10-12 Amcol International Corporation Compositions a liberation controlee amelioree
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
FR2795326B1 (fr) * 1999-06-28 2001-08-31 Adir Composition pharmaceutique solide thermoformable a liberation controlee
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
DE19940944B4 (de) * 1999-08-31 2006-10-12 Grünenthal GmbH Retardierte, orale, pharmazeutische Darreichungsformen
DE19943501A1 (de) * 1999-09-10 2001-03-15 Basf Ag Unterwassergranulation wirkstoffhaltiger Schmelzen
US6500463B1 (en) 1999-10-01 2002-12-31 General Mills, Inc. Encapsulation of sensitive components into a matrix to obtain discrete shelf-stable particles
KR20020059653A (ko) 1999-10-29 2002-07-13 그린 마틴, 브라이언 쥐 테슬리 서방성 하이드로코돈 제형
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
US6491953B1 (en) 2000-01-07 2002-12-10 Amcol International Corporation Controlled release compositions and method
US6953593B2 (en) * 2000-02-01 2005-10-11 Lipoprotein Technologies, Inc. Sustained-release microencapsulated delivery system
BRPI0108380B8 (pt) * 2000-02-08 2021-05-25 Euro Celtique S/A fórmulas de opióides agonistas resistentes à adulteração, método para diminuir o abuso de um opióide agonista numa fórmula de dosagem oral, método de preparação de uma fórmula de dosagem oral e método de tratamento da dor
CA2401288A1 (fr) * 2000-02-28 2001-09-07 Vectura Limited Ameliorations apportees a l'administration de medicaments par voie orale
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US6436453B1 (en) 2000-06-16 2002-08-20 General Mills, Inc. Production of oil encapsulated minerals and vitamins in a glassy matrix
US6468568B1 (en) 2000-06-16 2002-10-22 General Mills, Inc. Oligosaccharide encapsulated mineral and vitamin ingredients
HU230686B1 (en) * 2000-10-30 2017-08-28 Euro Celtique Sa Controlled release hydrocodone compositions
FR2818552B1 (fr) * 2000-12-26 2003-02-07 Servier Lab Compositions pharmaceutique solide thermoformable pour la liberation controlee d'ivabradine
FR2818550B1 (fr) * 2000-12-26 2003-02-07 Servier Lab Composition pharmaceutique solide thermoformable pour la liberation controle de perindopril
FR2818549B1 (fr) * 2000-12-26 2003-02-07 Servier Lab Composition pharmaceutique solide thermoformable pour la liberation controlee de trimetazidine
JP2004537338A (ja) * 2001-03-02 2004-12-16 ユーロ−セルティーク，エス．エイ． 個別の投与剤形を調合するための方法と装置
AU2002234219A1 (en) * 2001-03-09 2002-09-24 Dow Global Technologies Inc. Granular composition comprising an active compound and a cellulose ether and the use thereof
US7858118B2 (en) * 2001-04-11 2010-12-28 Galephar Pharmaceutical Research, Inc. Extended release composition containing Tramadol
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US20110104214A1 (en) * 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
WO2002092060A1 (fr) 2001-05-11 2002-11-21 Endo Pharmaceuticals, Inc. Forme posologique d'opioides a liberation prolongee empechant la consommation abusive
US20030070584A1 (en) 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
AUPR510001A0 (en) * 2001-05-18 2001-06-14 Jupitar Pty Ltd Formulation and method
JP4310605B2 (ja) 2001-05-25 2009-08-12 大塚製薬株式会社 医薬用組成物
AU2002314967B2 (en) 2001-06-05 2007-09-20 University Of Chicago Use of methylnaltrexone to treat immune suppression
GB0113841D0 (en) * 2001-06-07 2001-08-01 Boots Co Plc Therapeutic agents
WO2003002100A1 (fr) * 2001-06-26 2003-01-09 Farrell John J Systeme d'administration de narcotique inviolable
US20030130297A1 (en) * 2001-07-06 2003-07-10 Endo Pharmaceuticals, Inc. Oral administration of 6-hydroxy-oxymorphone for use as an analgesic
EP1404332A1 (fr) * 2001-07-06 2004-04-07 Penwest Pharmaceuticals Company Procedes de preparation de compositions a liberation entretenue d'oxymorphone
US8329216B2 (en) 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
DK1416842T3 (da) 2001-07-18 2009-03-16 Euro Celtique Sa Farmaceutiske kombinationer af oxycodon og naloxon
ATE431738T1 (de) 2001-08-06 2009-06-15 Euro Celtique Sa Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
WO2003013433A2 (fr) 2001-08-06 2003-02-20 Euro-Celtique S.A. Formulations d'antagoniste sequestre
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US7157103B2 (en) * 2001-08-06 2007-01-02 Euro-Celtique S.A. Pharmaceutical formulation containing irritant
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
WO2003024430A1 (fr) 2001-09-21 2003-03-27 Egalet A/S Systeme a liberation de polymere de morphine
EP1429739A1 (fr) 2001-09-21 2004-06-23 Egalet A/S Systeme de liberation a base de polymere
US20030091635A1 (en) * 2001-09-26 2003-05-15 Baichwal Anand R. Opioid formulations having reduced potential for abuse
US8309118B2 (en) 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
US7491407B2 (en) * 2001-10-31 2009-02-17 North Carolina State University Fiber-based nano drug delivery systems (NDDS)
HRP20020124A2 (en) * 2002-02-11 2003-10-31 Pliva D D Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping
US8128957B1 (en) 2002-02-21 2012-03-06 Valeant International (Barbados) Srl Modified release compositions of at least one form of tramadol
US20050182056A9 (en) * 2002-02-21 2005-08-18 Seth Pawan Modified release formulations of at least one form of tramadol
DE10208344A1 (de) * 2002-02-27 2003-09-04 Roehm Gmbh Schmelzextrusion von Wirkstoffsalzen
PT2425821T (pt) * 2002-04-05 2017-08-23 Mundipharma Farmacêutica Lda Preparação farmacêutica contendo oxicodona e naloxona
WO2003090717A1 (fr) * 2002-04-23 2003-11-06 Nanotherapeutics, Inc Procede de formation et de modification de particules et compositions produites au moyen de ce procede
AU2003245345A1 (en) * 2002-05-31 2003-12-19 Alza Corporation Dosage forms and compositions for osmotic delivery of variable dosages of oxycodone
US7776314B2 (en) * 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
GB0214013D0 (en) * 2002-06-18 2002-07-31 Euro Celtique Sa Pharmaceutical product
US10004729B2 (en) 2002-07-05 2018-06-26 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US8557291B2 (en) 2002-07-05 2013-10-15 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opioids and other drugs
US8840928B2 (en) * 2002-07-05 2014-09-23 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
AU2003247876B2 (en) 2002-07-05 2006-10-05 Collegium Pharmaceutical, Inc Abuse-deterrent pharmaceutical compositions of opiods and other drugs
CA2498798A1 (fr) * 2002-09-20 2004-04-01 Alpharma, Inc. Formulation opioides a liberation prolongee et procedes d'utilisation connexes
ES2677769T3 (es) 2002-09-20 2018-08-06 Alpharma Pharmaceuticals Llc Subunidad secuestrante y composiciones y procedimientos relacionados
US20090162431A1 (en) * 2002-09-21 2009-06-25 Shuyi Zhang Sustained release formulations containing acetaminophen and tramadol
JP5189242B2 (ja) * 2002-09-23 2013-04-24 アルケルメス ファーマ アイルランド リミテッド 乱用抵抗性の医薬組成物
US8487002B2 (en) * 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
TWI319713B (en) * 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
EP1575569B1 (fr) 2002-12-13 2010-09-29 Durect Corporation Forme d'administration orale de medicaments comprenant un vehicule liquide de haute viscosite
US20040115287A1 (en) * 2002-12-17 2004-06-17 Lipocine, Inc. Hydrophobic active agent compositions and methods
DE10300325A1 (de) 2003-01-09 2004-07-22 Hexal Ag Granulat mit öliger Substanz, Herstellungsverfahren und Tablette
US20060153915A1 (en) * 2003-01-23 2006-07-13 Amorepacific Corporation Sustained-release preparations and method for producing the same
US7136656B2 (en) * 2003-03-20 2006-11-14 Interdigital Technology Corporation Method of fast dynamic channel allocation call admission control for radio link addition in radio resource management
WO2004084868A1 (fr) 2003-03-26 2004-10-07 Egalet A/S Systeme de liberation regulee de morphine
JP2006522099A (ja) * 2003-04-04 2006-09-28 ファルマシア コーポレーション 複合粒状体からなる経口徐放性圧縮錠
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
MXPA05010821A (es) * 2003-04-08 2006-03-30 Progenics Pharm Inc Terapia de combinacion para constipacion que comprende un laxante y un antagonista opioide periferico.
RU2362560C2 (ru) 2003-04-08 2009-07-27 Проджиникс Фармасьютикалз, Инк. Фармацевтическая препаративная форма
AU2004229462A1 (en) * 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome
TWI347201B (en) 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same
CA2519556C (fr) 2003-04-21 2011-01-18 Benjamin Oshlack Forme posologique inviolable contenant des particules co-extrudees d'agent repulsif contraire et procede de fabrication
US20060165790A1 (en) * 2003-06-27 2006-07-27 Malcolm Walden Multiparticulates
TWI357815B (en) * 2003-06-27 2012-02-11 Euro Celtique Sa Multiparticulates
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
NZ545202A (en) * 2003-08-06 2010-03-26 Gruenenthal Chemie Abuse-proofed dosage form comprising opiods and a high molecular weight polyethylene oxide
DE102004020220A1 (de) * 2004-04-22 2005-11-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE102005005446A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
US20050089558A1 (en) * 2003-10-28 2005-04-28 Alamo Pharmaceuticals, Llc Compositions and methods for the co-formulation and administration of tramadol and propoxyphene
WO2005053639A2 (fr) * 2003-12-04 2005-06-16 Pfizer Products Inc. Formes multiparticulaires a liberation controlee produites avec des optimiseurs de dissolution
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
BRPI0417348A (pt) 2003-12-04 2007-03-13 Pfizer Prod Inc processo de gelatinização por spray com utilização de uma extrusora para preparação de composições de droga cristalina multiparticulada contendo preferencialmente um poloxámero e um glicerìdeo
MXPA06005913A (es) * 2003-12-04 2006-06-27 Pfizer Prod Inc Formas de dosificacion de multiparticulas de azitromicina por procedimientos basados en liquidos.
BRPI0416534A (pt) * 2003-12-04 2007-01-09 Pfizer Prod Inc composições multiparticuladas com estabilidade melhorada
PL1691787T3 (pl) 2003-12-04 2008-11-28 Pfizer Prod Inc Sposób wytwarzania farmaceutycznych systemów wielocząstkowych
KR20080064209A (ko) * 2003-12-04 2008-07-08 화이자 프로덕츠 인코포레이티드 바람직하게는 폴록사머와 글리세라이드를 함유하는다미립자 아지트로마이신 조성물의 제조를 위해 압출기를사용하는 분무응결 방법
WO2005053652A1 (fr) 2003-12-04 2005-06-16 Pfizer Products Inc. Compositions medicamenteuses cristallines multiparticulaires contenant un poloxamere et un glyceride
EP1691892B1 (fr) * 2003-12-09 2007-02-28 Euro-Celtique S.A. Forme posologique co-extrudee inviolable contenant un principe actif et un principe contraire, et procede de fabrication
US8883204B2 (en) * 2003-12-09 2014-11-11 Purdue Pharma L.P. Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same
GB0403098D0 (en) * 2004-02-12 2004-03-17 Euro Celtique Sa Extrusion
TWI350762B (en) * 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
GB0501638D0 (en) * 2005-01-28 2005-03-02 Euro Celtique Sa Particulates
GB0403100D0 (en) * 2004-02-12 2004-03-17 Euro Celtique Sa Particulates
KR100963914B1 (ko) * 2004-03-30 2010-06-17 유로-셀띠끄 소시에떼 아노님 흡착제 및 억제제를 포함하는 내변조성 제형
EP1604666A1 (fr) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioides pour le traitement de la bronchopneumopathie chronique obstructive
EP1604667A1 (fr) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioides pour le traitement des impatiences des membres inférieurs
WO2005123039A1 (fr) * 2004-06-12 2005-12-29 Collegium Pharmaceutical, Inc. Formulations de prevention des abus
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
JP5259183B2 (ja) * 2004-07-01 2013-08-07 グリューネンタール・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 乱用に対して保護された経口剤形
EP1771159A4 (fr) * 2004-07-22 2009-04-29 Amorepacific Corp Preparations a liberation lente contenant du topiramate et procede de fabrication
GB2418854B (en) * 2004-08-31 2009-12-23 Euro Celtique Sa Multiparticulates
WO2006028830A2 (fr) * 2004-09-01 2006-03-16 Euro-Celtique S.A. Posologies d'opioides comportant un etat stationnaire cave proportionnel de dosage et de surface sous la courbe et inferieur a une dose unique proportionnelle de dosage cmax
TWI436991B (zh) 2004-11-22 2014-05-11 Euro Celtique Sa 用於純化反-（-）-△９-四氫大麻酚與反-（＋）-△９-四氫大麻酚之方法
US20070129402A1 (en) * 2004-12-27 2007-06-07 Eisai Research Institute Sustained release formulations
RU2401125C2 (ru) 2004-12-27 2010-10-10 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Способ стабилизации лекарственного средства против деменции
TWI432196B (zh) * 2005-01-18 2014-04-01 Euro Celtique Sa 內臟痛的治療
MX2007008756A (es) * 2005-01-20 2007-09-27 Progenics Pharm Inc Uso de metilnaltrexona y compuestos relacionados para el tratamiento de disfuncion gastrointestinal postoperatoria.
EP3228308A1 (fr) * 2005-01-28 2017-10-11 Euro-Celtique S.A. Formes posologiques résistantes à l'alcool
DE102005005449A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
EP1702558A1 (fr) 2005-02-28 2006-09-20 Euro-Celtique S.A. Procédé et dispositif pour évaluer la fonction de l'activité intestinale
EP1695700A1 (fr) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Forme posologique contenant de l'oxycodone et de la naloxone
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
AU2006220682B2 (en) 2005-03-07 2012-05-31 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
WO2006118265A1 (fr) * 2005-04-28 2006-11-09 Eisai R & D Management Co., Ltd. Composition contenant un agent anti-démence
GB0509276D0 (en) * 2005-05-06 2005-06-15 Univ Cranfield Synthetic receptor
CN101166517B (zh) * 2005-05-10 2012-01-04 诺瓦提斯公司 制备含有可压性差的治疗性化合物的组合物的挤压方法
AU2011224098B2 (en) * 2005-05-10 2013-10-31 Novartis Ag Extrusion process for making compositions with poorly compressible therapeutic compounds
NZ562304A (en) * 2005-05-10 2010-06-25 Novartis Ag Extrusion process for making compositions with poorly compressible therapeutic compounds e.g. metformin hydrochloride
US20060286148A1 (en) * 2005-05-18 2006-12-21 Ppd, Inc. Method of forming implants
AR057325A1 (es) * 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
US20080194611A1 (en) * 2005-06-03 2008-08-14 Alverdy John C Modulation of Cell Barrier Dysfunction
PT1888080E (pt) * 2005-06-09 2010-07-06 Euro Celtique Sa ComposiãŽes farmac—uticas de um esterëide neuroactivo e as suas utilizaãŽes
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
US7884136B2 (en) 2005-06-27 2011-02-08 Biovail Laboratories International S.R.L. Modified-release formulations of a bupropion salt
US8394812B2 (en) 2005-08-24 2013-03-12 Penwest Pharmaceuticals Co. Sustained release formulations of nalbuphine
WO2007025005A2 (fr) 2005-08-24 2007-03-01 Penwest Pharmaceuticals Co. Formulations de nalbuphine a liberation prolongee
DK1940467T3 (da) 2005-09-09 2017-02-13 Paladin Labs Inc Lægemiddelsammensætning med langvarig frigivelse
JP5523706B2 (ja) * 2005-09-23 2014-06-18 エフ．ホフマン−ラ ロシュ アーゲー 新規投薬配合物
KR100656019B1 (ko) * 2005-10-20 2006-12-08 현대자동차주식회사 신규의 폴리이미드-폴리벤지이미다졸의 공중합체와, 이를이용한 고분자 전해질 막
US20070160960A1 (en) * 2005-10-21 2007-07-12 Laser Shot, Inc. System and method for calculating a projectile impact coordinates
PL116330U1 (en) * 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
GB2431875A (en) * 2005-10-31 2007-05-09 Alza Corp Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms
US7803413B2 (en) 2005-10-31 2010-09-28 General Mills Ip Holdings Ii, Llc. Encapsulation of readily oxidizable components
CN1957909B (zh) * 2005-10-31 2013-09-11 阿尔扎公司 降低鸦片样物质持续释放口服剂型的由醇诱导的剂量突然释放的方法
WO2007056142A2 (fr) * 2005-11-02 2007-05-18 Theraquest Biosciences, Llc Procedes de prevention du syndrome serotoninergique et compositions utilisees a cette fin
WO2007087452A2 (fr) * 2006-01-27 2007-08-02 Theraquest Biosciences, Llc Formulations à libération prolongée empêchant l'usage abusif et méthodes d'utilisation de celles-ci
US9125833B2 (en) 2005-11-02 2015-09-08 Relmada Therapeutics, Inc. Multimodal abuse resistant and extended release opioid formulations
US8329744B2 (en) 2005-11-02 2012-12-11 Relmada Therapeutics, Inc. Methods of preventing the serotonin syndrome and compositions for use thereof
US7811604B1 (en) 2005-11-14 2010-10-12 Barr Laboratories, Inc. Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same
EP1810678A1 (fr) 2006-01-19 2007-07-25 Holger Lars Hermann Utilisation de morphine et naloxone pour la substitution de médicaments
US20100172989A1 (en) * 2006-01-21 2010-07-08 Abbott Laboratories Abuse resistant melt extruded formulation having reduced alcohol interaction
WO2007085024A2 (fr) * 2006-01-21 2007-07-26 Abbott Gmbh & Co. Kg Forme dosifiée et méthode d'administration de drogues toxicomanogènes
US20090022798A1 (en) * 2007-07-20 2009-01-22 Abbott Gmbh & Co. Kg Formulations of nonopioid and confined opioid analgesics
US20090317355A1 (en) * 2006-01-21 2009-12-24 Abbott Gmbh & Co. Kg, Abuse resistant melt extruded formulation having reduced alcohol interaction
US20070185145A1 (en) * 2006-02-03 2007-08-09 Royds Robert B Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same
US20070190141A1 (en) * 2006-02-16 2007-08-16 Aaron Dely Extended release opiate composition
US20070212414A1 (en) * 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
FI20060501L (fi) * 2006-05-22 2007-11-23 Biohit Oyj Koostumus ja menetelmä asetaldehydin sitomiseksi vatsassa
EP1859788A1 (fr) * 2006-05-24 2007-11-28 Abbott GmbH & Co. KG Production des formes galéniques enrobées
US20080069891A1 (en) * 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
ES2385612T3 (es) 2006-06-19 2012-07-27 Alpharma Pharmaceuticals, Llc Composiciones farmacéuticas
US20080020032A1 (en) * 2006-07-21 2008-01-24 Michael Crowley Hydrophobic abuse deterrent delivery system for hydromorphone
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
US8128460B2 (en) * 2006-09-14 2012-03-06 The Material Works, Ltd. Method of producing rust inhibitive sheet metal through scale removal with a slurry blasting descaling cell
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
US20080081067A1 (en) * 2006-10-03 2008-04-03 Gupta Manishkumar Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
CA2665841C (fr) 2006-10-09 2016-04-05 Charleston Laboratories, Inc. Compositions pharmaceutiques
DE102007009242A1 (de) * 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit magensaftresistenter Wirkstoff-Matix
DE102007009243A1 (de) * 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit einer Wirkstoff-Matrix und einem Polymerüberzug, sowie ein Verfahren zur Herstellung der Pellets
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
GB2447898B (en) * 2007-03-24 2011-08-17 Reckitt Benckiser Healthcare A tablet having improved stability with at least two actives
PE20090700A1 (es) 2007-03-29 2009-07-13 Progenics Pharm Inc Compuestos heterociclicos como antagonistas del receptor opioide periferico
US20100305323A1 (en) 2007-03-29 2010-12-02 Smolenskaya Valeriya N Crystal forms of (r)-n-methylnaltrexone bromide and uses thereof
CA2682550C (fr) 2007-03-29 2016-05-17 Wyeth Recepteur et antagonistes d'opioide peripheriques et utilisations de ceux-ci
DE102007025858A1 (de) * 2007-06-01 2008-12-04 Grünenthal GmbH Verfahren zur Herstellung einer Arzneimitteldarreichungsform
WO2008148798A2 (fr) 2007-06-04 2008-12-11 Egalet A/S Compositions pharmaceutiques à libération contrôlée pour un effet prolongé
DE102007026550A1 (de) * 2007-06-08 2008-12-11 Bayer Healthcare Ag Extrudate mit verbesserter Geschmacksmaskierung
US20090124650A1 (en) * 2007-06-21 2009-05-14 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
ES2572157T3 (es) * 2007-09-03 2016-05-30 Nanotherapeutics Inc Composiciones en forma de partículas para la administración de fármacos poco solubles
CA2702904A1 (fr) 2007-10-19 2009-04-23 Otsuka Pharmaceutical Co., Ltd. Preparation pharmaceutique solide de type matrice
US8415401B2 (en) 2007-12-06 2013-04-09 Durect Corporation Oral pharmaceutical dosage forms
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
EP2224808A4 (fr) * 2007-12-17 2013-11-27 Alpharma Pharmaceuticals Llc Composition pharmaceutique
JP5714910B2 (ja) 2008-01-09 2015-05-07 チャールストン ラボラトリーズ，インコーポレイテッド 薬学的組成物
TW200950776A (en) * 2008-01-24 2009-12-16 Abbott Gmbh & Co Kg Abuse resistant melt extruded formulation having reduced alcohol interaction
EP2249811A1 (fr) 2008-01-25 2010-11-17 Grünenthal GmbH Forme posologique pharmaceutique
US20090246276A1 (en) * 2008-01-28 2009-10-01 Graham Jackson Pharmaceutical Compositions
US9226907B2 (en) 2008-02-01 2016-01-05 Abbvie Inc. Extended release hydrocodone acetaminophen and related methods and uses thereof
WO2009099411A1 (fr) 2008-02-06 2009-08-13 Progenics Pharmaceuticals, Inc. Préparation et utilisation de (r),(r)-2,2'-bis-méthylnaltrexone
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
EP2262484B1 (fr) 2008-03-11 2013-01-23 Depomed, Inc. Formes médicamenteuses à libération étendue de rétention gastrique comprenant des combinaisons d'un analgésique non opioïde et d'un analgésique opioïde
CA2719134C (fr) 2008-03-21 2015-06-30 The University Of Chicago Traitement avec des antagonistes des opioides et des inhibiteurs mtor
EP2280681A1 (fr) * 2008-04-30 2011-02-09 Novartis AG Procédé continu de fabrication de compositions pharmaceutiques
CN102123701B (zh) 2008-05-09 2013-03-27 格吕伦塔尔有限公司 使用喷雾冻凝步骤制备中间粉末制剂以及最终固体剂型的方法
WO2010003078A2 (fr) * 2008-07-03 2010-01-07 Novartis Ag Processus de granulation par fusion
ES2635733T3 (es) * 2008-07-07 2017-10-04 Euro-Celtique S.A. Uso de antagonistas opioideos para tratar la retención urinaria
WO2010022193A2 (fr) 2008-08-20 2010-02-25 Board Of Regents, The University Of Texas System Extrusion à chaud de multiparticules à libération modifiée
CN102202654B (zh) * 2008-09-04 2014-07-30 法纳姆公司 可咀嚼的缓释制剂
ES2586439T3 (es) * 2008-09-18 2016-10-14 Purdue Pharma Lp Formas farmacéuticas de dosificación que comprenden poli (E-caprolactona)
CA2676881C (fr) 2008-09-30 2017-04-25 Wyeth Antagonistes de recepteurs opioides peripheriques, et leurs utilisations
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
EP2381937A2 (fr) 2008-12-31 2011-11-02 Upsher-Smith Laboratories, Inc. Compositions pharmaceutiques orales contenant un opioïde et procédés
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US9005660B2 (en) 2009-02-06 2015-04-14 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
ES2706407T3 (es) 2009-03-10 2019-03-28 Euro Celtique Sa Composiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona
GB0909680D0 (en) 2009-06-05 2009-07-22 Euro Celtique Sa Dosage form
US9743228B2 (en) 2009-06-22 2017-08-22 Qualcomm Incorporated Transport of LCS-related messages for LTE access
CA2766179A1 (fr) 2009-06-24 2010-12-29 Egalet Ltd. Formulations a liberation controlee
WO2011006012A1 (fr) 2009-07-08 2011-01-13 Charleston Laboratories Inc. Compositions pharmaceutiques
NZ596667A (en) 2009-07-22 2013-09-27 Gruenenthal Chemie Hot-melt extruded controlled release dosage form
JP2012533585A (ja) 2009-07-22 2012-12-27 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 酸化感受性オピオイドのための不正使用防止剤形
US20110052685A1 (en) * 2009-08-31 2011-03-03 Depomed, Inc. Gastric retentive pharmaceutical compositions for immediate and extended release of acetaminophen
US9023390B2 (en) 2009-09-17 2015-05-05 Upsher-Smith Laboratories, Inc. Sustained-release product comprising a combination of a non-opioid amine and a non-steroidal anti-inflammatory drug
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
ES2606227T3 (es) 2010-02-03 2017-03-23 Grünenthal GmbH Preparación de una composición farmacéutica en polvo mediante una extrusora
US9993433B2 (en) 2010-05-10 2018-06-12 Euro-Celtique S.A. Manufacturing of active-free granules and tablets comprising the same
BR112012028773A2 (pt) 2010-05-10 2016-07-19 Euro Celtique Sa composições farmacêuticas compreendendo hidromorfona e naloxona
JP5840201B2 (ja) 2010-05-10 2016-01-06 ユーロ−セルティーク エス．エイ． 活性剤を負荷した顆粒と追加の活性剤の組合せ
US8927025B2 (en) 2010-05-11 2015-01-06 Cima Labs Inc. Alcohol-resistant metoprolol-containing extended-release oral dosage forms
KR20130137627A (ko) 2010-09-02 2013-12-17 그뤼넨탈 게엠베하 음이온성 중합체를 포함하는 내변조성 투여형
CA2808219C (fr) 2010-09-02 2019-05-14 Gruenenthal Gmbh Forme pharmaceutique inviolable comportant un sel inorganique
JP2013537915A (ja) * 2010-09-24 2013-10-07 キューアールエックスファーマ リミテッド オピオイドの制御放出製剤
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
GB201020895D0 (en) * 2010-12-09 2011-01-26 Euro Celtique Sa Dosage form
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
RS56344B1 (sr) 2010-12-22 2017-12-29 Purdue Pharma Lp Obloženi dozni oblici sa kontrolisanim oslobađanjem otporni na zloupotrebu
KR20140075807A (ko) 2010-12-23 2014-06-19 퍼듀 퍼머 엘피 탬퍼 저항성 고체 경구 투여 형태
US8658631B1 (en) 2011-05-17 2014-02-25 Mallinckrodt Llc Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
AT511581A1 (de) 2011-05-26 2012-12-15 G L Pharma Gmbh Orale retardierende formulierung
US8758826B2 (en) * 2011-07-05 2014-06-24 Wet Inc. Cannabinoid receptor binding agents, compositions, and methods
NO2736497T3 (fr) 2011-07-29 2018-01-20
CN103841964A (zh) 2011-07-29 2014-06-04 格吕伦塔尔有限公司 提供药物立即释放的抗破碎片剂
EP2755640B1 (fr) * 2011-09-16 2017-07-26 Purdue Pharma LP Formulations pharmaceutiques inviolables
AU2012328837B2 (en) * 2011-10-26 2015-07-09 Kempharm, Inc. Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydromorphone, prodrugs, methods of making and use thereof
CA2864949A1 (fr) 2012-02-28 2013-09-06 Grunenthal Gmbh Forme pharmaceutique inviolable comprenant un compose pharmacologiquement actif et un polymere anionique
EA028224B1 (ru) * 2012-03-02 2017-10-31 Роудс Фармасьютикалз Л.П. Лекарственные формы немедленного высвобождения с защитой от несанкционированного применения
WO2013156850A1 (fr) 2012-04-17 2013-10-24 Purdue Pharma L.P. Systèmes et procédés de traitement d'une réponse pharmacodynamique indésirable induite par un opioïde
CA2868142A1 (fr) 2012-04-18 2013-10-24 Grunenthal Gmbh Forme pharmaceutique inviolable et resistante a la liberation massive
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
EP2877161A1 (fr) 2012-07-06 2015-06-03 Egalet Ltd. Compositions pharmaceutiques de dissuasion d'abus à libération contrôlée
PL2872121T3 (pl) 2012-07-12 2019-02-28 SpecGx LLC Kompozycje farmaceutyczne o przedłużonym uwalnianiu, zniechęcające do nadużywania
US10702453B2 (en) 2012-11-14 2020-07-07 Xerox Corporation Method and system for printing personalized medication
WO2014102745A1 (fr) * 2012-12-31 2014-07-03 Aizant Drug Research Solutions Private Limited Composition d'ibuprofène à libération prolongée à forte charge de médicament
KR101659983B1 (ko) 2012-12-31 2016-09-26 주식회사 삼양바이오팜 용융 압출된 방출 제어용 약학 조성물, 및 이를 포함하는 경구용 제제
BR112015017451B1 (pt) 2013-02-05 2023-01-10 Purdue Pharma L.P. Formulações farmacêuticas resistentes à violação
CN105120659A (zh) 2013-03-15 2015-12-02 度瑞公司 用于降低溶解可变性的具有流变改性剂的组合物
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
AU2014273226B2 (en) 2013-05-29 2019-06-27 Grunenthal Gmbh Tamper resistant dosage form with bimodal release profile
BR112015026549A2 (pt) 2013-05-29 2017-07-25 Gruenenthal Gmbh forma de dosagem à prova de violação contendo uma ou mais partículas
WO2015004245A1 (fr) 2013-07-12 2015-01-15 Grünenthal GmbH Forme posologique inviolable contenant un polymère d'éthylène-acétate de vinyle
NZ716267A (en) 2013-07-23 2017-05-26 Euro Celtique Sa A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
US10195153B2 (en) 2013-08-12 2019-02-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
WO2015065547A1 (fr) 2013-10-31 2015-05-07 Cima Labs Inc. Formes pharmaceutiques en granulés anti-abus à libération immédiate
US9814710B2 (en) 2013-11-13 2017-11-14 Euro-Celtique S.A. Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
BR112016010482B1 (pt) 2013-11-26 2022-11-16 Grünenthal GmbH Preparação de uma composição farmacêutica em pó por meio de criomoagem
WO2015095391A1 (fr) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Comprimé extrudé anti-abus à libération prolongée
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015173195A1 (fr) 2014-05-12 2015-11-19 Grünenthal GmbH Formulation pour capsule à libération immédiate résistant aux manipulations illicites comprenant du tapentadol
AU2015266117A1 (en) 2014-05-26 2016-11-24 Grunenthal Gmbh Multiparticles safeguarded against ethanolic dose-dumping
CA2955229C (fr) 2014-07-17 2020-03-10 Pharmaceutical Manufacturing Research Services, Inc. Forme posologique remplie de liquide anti-abus a liberation immediate
WO2016033549A2 (fr) 2014-08-28 2016-03-03 Lipocine Inc. Compositions de (17-ss)-3-oxoandrost-4-èn-17-yl tridécanoate et leurs procédés de préparation et d'utilisation
WO2016033556A1 (fr) 2014-08-28 2016-03-03 Lipocine Inc. Esters de (17-β)-hydroxy-4-androstène-3-one biodisponibles à l'état solide
CH710097A2 (de) * 2014-09-12 2016-03-15 Chemspeed Technologies Ag Verfahren und Vorrichtung zur Herstellung eines Extrudats.
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
EP3206491B1 (fr) 2014-10-17 2019-11-27 Salix Pharmaceuticals, Inc. Utilisation de méthylnaltrexone pour atténuer une progression de tumeur
EP3209282A4 (fr) 2014-10-20 2018-05-23 Pharmaceutical Manufacturing Research Services, Inc. Forme galénique anti-abus de remplissage de liquide à libération prolongée
BR112017011764A2 (pt) 2014-12-02 2018-07-10 Kempharm, Inc. ácido benzóico, derivados de ácido benzóico e conjugados de ácido heteroaril carboxílico de oximorfona, pro-fármacos, métodos e preparação e uso dos mesmos
EP3285745A1 (fr) 2015-04-24 2018-02-28 Grünenthal GmbH Forme galénique inviolable avec libération immédiate et résistance à l'extraction par solvant.
EP3346991A1 (fr) 2015-09-10 2018-07-18 Grünenthal GmbH Protection contre un surdosage par voie orale à l'aide de formulations à libération immédiate dissuasives d'abus
US9943513B1 (en) 2015-10-07 2018-04-17 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
EP3423041A4 (fr) 2016-03-04 2019-09-11 Charleston Laboratories, Inc. Compositions pharmaceutiques
AU2017241266B2 (en) 2016-03-31 2022-02-10 SpecGx LLC Extended release, abuse deterrent dosage forms
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
WO2017222575A1 (fr) 2016-06-23 2017-12-28 Collegium Pharmaceutical, Inc. Procédé de préparation de formulations orales dissuasives d'abus plus stables
US20180147215A1 (en) 2016-11-28 2018-05-31 Lipocine Inc. Oral testosterone undecanoate therapy
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
WO2019087084A1 (fr) 2017-11-02 2019-05-09 Eman Biodiscoveries Sd. Bhd. Extrait d'orthosiphon stamineus, formulations et leurs utilisations
US20220062200A1 (en) 2019-05-07 2022-03-03 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
WO2020225773A1 (fr) 2019-05-07 2020-11-12 Clexio Biosciences Ltd. Formes posologiques dissuasives d'abus contenant de l'eskétamine
CN110755396B (zh) * 2019-12-06 2022-04-08 北京悦康科创医药科技股份有限公司 一种布洛芬缓释小丸及其制备方法
JP7487290B2 (ja) * 2020-03-11 2024-05-20 沢井製薬株式会社 顆粒及びそれを用いた製剤
CN113080436B (zh) * 2021-04-08 2024-03-01 南京纽邦生物科技有限公司 γ-氨基丁酸干混悬剂及其制备方法

Family Cites Families (222)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US33093A (en) * 1861-08-20 Improvement in potato-diggers
US2738303A (en) * 1952-07-18 1956-03-13 Smith Kline French Lab Sympathomimetic preparation
US2743303A (en) * 1955-04-01 1956-04-24 Du Pont Process for the preparation of 1, 1, 4, 4-tetrafluorobutadiene 1, 3 from acetylene and tetrafluoroethylene
US3065143A (en) * 1960-04-19 1962-11-20 Richardson Merrell Inc Sustained release tablet
US4132753A (en) * 1965-02-12 1979-01-02 American Cyanamid Company Process for preparing oral sustained release granules
US3652589A (en) * 1967-07-27 1972-03-28 Gruenenthal Chemie 1-(m-substituted phenyl)-2-aminomethyl cyclohexanols
US3830934A (en) * 1967-07-27 1974-08-20 Gruenenthal Chemie Analgesic and antitussive compositions and methods
US3714350A (en) * 1969-03-10 1973-01-30 Mobil Oil Corp Phosphoryl and thiophosphoryl pyrones as insecticides
US3880991A (en) * 1969-03-24 1975-04-29 Brook David E Polymeric article for dispensing drugs
US4344431A (en) * 1969-03-24 1982-08-17 University Of Delaware Polymeric article for dispensing drugs
GB1357737A (en) * 1970-10-09 1974-06-26 Arpic Sa Sustained release pharmaceutical compositions
GB1405088A (en) 1971-06-03 1975-09-03 Mundipharma Ag Slow release formulation
FR2183546B1 (fr) * 1972-05-10 1975-06-20 Servier Lab
US3965256A (en) * 1972-05-16 1976-06-22 Synergistics Slow release pharmaceutical compositions
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4450150A (en) * 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
DE2360796B2 (de) * 1973-12-06 1977-06-02 Edelfettwerke Werner Schlüter, 2000 Hamburg; Glyco Iberica S.A., Gava, Barcelona (Spanien) Vti: Hegel, K.Th., Dr.; Dickel, K., Dipl.-Ing.; Pat.-Anwälte, 2000 Hamburg und 8000 München Arzneimittel mit verzoegerter abgabe des wirkstoffs im darm
US3974157A (en) * 1974-03-04 1976-08-10 Pennwalt Corporation 1-(Amino-alkyl)-2-aryl-cyclohexane alcohols and esters
DE2426812A1 (de) 1974-06-04 1976-01-02 Klinge Co Chem Pharm Fab Verfahren zur herstellung von granulaten
DE2426811A1 (de) 1974-06-04 1976-01-08 Klinge Co Chem Pharm Fab Verfahren zur herstellung von retard-tabletten
DE2439538C3 (de) 1974-08-17 1980-07-17 Ludwig Heumann & Co Gmbh, 8500 Nuernberg Verfahren zur Herstellung von oral zu verabreichenden Arzneimitteln mit verzögerter Wirkungsfreigabe
US4076798A (en) * 1975-05-29 1978-02-28 American Cyanamid Company High molecular weight polyester resin, the method of making the same and the use thereof as a pharmaceutical composition
GB1504553A (en) 1975-11-17 1978-03-22 Sandoz Ltd Tablet formulations
US4406883A (en) * 1976-07-23 1983-09-27 Merrell Dow Pharmaceuticals Inc. Controlled release suppositories consisting essentially of a linear polymer particularly, polyvinyl pyrrolidones
GB1593261A (en) * 1976-07-23 1981-07-15 Inveresk Res Int Controlled release suppository
US4173417A (en) * 1977-04-15 1979-11-06 Hpm Corporation Extrusion apparatus and method
US4366172A (en) * 1977-09-29 1982-12-28 The Upjohn Company 4-Amino-cyclohexanols, their pharmaceutical compositions and methods of use
US4230687A (en) * 1978-05-30 1980-10-28 Griffith Laboratories U.S.A., Inc. Encapsulation of active agents as microdispersions in homogeneous natural polymeric matrices
EP0008083A1 (fr) * 1978-08-15 1980-02-20 Ciba-Geigy Ag Procédé de préparation de granulés d'additifs fondant difficilement pour des matières plastiques, en particulier de pigments, par une granulation thermique par rotation, et les granulés ainsi obtenus
CH637014A5 (de) 1978-09-29 1983-07-15 Sandoz Ag Verfahren zur herstellung von suppositorien.
DE2923279B1 (de) 1979-06-08 1980-11-20 Kali Chemie Pharma Gmbh Verfahren zur Herstellung von Pankreatin-Pellets
CA1146866A (fr) 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Procede de production d'un compose pharmaceutique a liberation continue sous forme solide
US4309405A (en) * 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4259314A (en) * 1979-12-10 1981-03-31 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals
IE49324B1 (en) 1979-12-19 1985-09-18 Euro Celtique Sa Controlled release compositions
US4457933A (en) * 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
JPS56140915A (en) * 1980-04-07 1981-11-04 Yamanouchi Pharmaceut Co Ltd Pharmaceutical preparation for solid drug
DE3024416C2 (de) * 1980-06-28 1982-04-15 Gödecke AG, 1000 Berlin Verfahren zur Herstellung von Arzneimitteln mit retardierter Wirkstoff-Freisetzung
US4346709A (en) * 1980-11-10 1982-08-31 Alza Corporation Drug delivery devices comprising erodible polymer and erosion rate modifier
JPS57171428A (en) * 1981-04-13 1982-10-22 Sankyo Co Ltd Preparation of coated solid preparation
DE3124983A1 (de) 1981-06-25 1983-01-20 Meditest Inst Fuer Medizinisch Arzneiformen zur oralen verabreichung
US4374082A (en) * 1981-08-18 1983-02-15 Richard Hochschild Method for making a pharmaceutical and/or nutritional dosage form
US4366159A (en) * 1981-09-08 1982-12-28 Michael Richard Magruder Nalbuphine-narcotic analgesic composition and method of producing analgesia
US4369172A (en) 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4987136A (en) * 1982-03-16 1991-01-22 The Rockefeller University Method for controlling gastrointestinal dysmotility
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4421736A (en) * 1982-05-20 1983-12-20 Merrel Dow Pharmaceuticals Inc. Sustained release diethylpropion compositions
US4443428A (en) 1982-06-21 1984-04-17 Euroceltique, S.A. Extended action controlled release compositions
AU1873783A (en) 1982-10-08 1984-04-12 Verex Laboratories Inc. Constant release formulation
US4469613A (en) * 1983-02-23 1984-09-04 International Flavors & Fragrances Inc. Detergent bar containing poly(epsilon caprolactone) and aromatizing agent
US4882167A (en) * 1983-05-31 1989-11-21 Jang Choong Gook Dry direct compression compositions for controlled release dosage forms
JPS6013838A (ja) * 1983-07-04 1985-01-24 Mitsui Petrochem Ind Ltd ポリプロピレン組成物
US4917899A (en) * 1983-12-22 1990-04-17 Elan Corporation Plc Controlled absorption diltiazem formulation
EP0147780A3 (fr) 1984-01-03 1987-03-11 Merck & Co. Inc. Dispositif pour la libération d'un médicament
EP0152379A3 (fr) 1984-02-15 1986-10-29 Ciba-Geigy Ag Procédé pour la préparation de compositions pharmaceutiques contenant des liposomes unilamellaires
GB8405112D0 (en) * 1984-02-28 1984-04-04 Akzo Nv Anti-arrhythmic amino-alcohols
US4649042A (en) * 1984-05-31 1987-03-10 Eli Lilly And Company Rumen delivery device
US4629621A (en) * 1984-07-23 1986-12-16 Zetachron, Inc. Erodible matrix for sustained release bioactive composition
US4894234A (en) * 1984-10-05 1990-01-16 Sharma Shri C Novel drug delivery system for antiarrhythmics
EP0189861A3 (fr) 1985-01-26 1988-02-17 Showa Denko Kabushiki Kaisha Promoteur d'absorption percutannée pour des médicaments ioniques hydrosolubles
US4772475A (en) 1985-03-08 1988-09-20 Yamanouchi Pharmaceutical Co., Ltd. Controlled-release multiple units pharmaceutical formulation
US4720384A (en) * 1985-05-03 1988-01-19 E. I. Du Pont De Nemours And Company Manufacture of hollow fine tubular drug delivery systems
FR2581541B1 (fr) * 1985-05-09 1988-05-20 Rhone Poulenc Sante Nouvelles compositions pharmaceutiques permettant la liberation prolongee d'un principe actif et leur procede de preparation
GB8514665D0 (en) * 1985-06-11 1985-07-10 Eroceltique Sa Oral pharmaceutical composition
JPS61293911A (ja) * 1985-06-24 1986-12-24 Teisan Seiyaku Kk 徐放化製剤
DE3524003A1 (de) * 1985-07-04 1987-01-08 Heumann Ludwig & Co Gmbh Arzneimittelgranulat mit verzoegerter wirkstofffreisetzung und verfahren zu seiner herstellung
FR2585246A1 (fr) 1985-07-26 1987-01-30 Cortial Procede d'obtention de formes pharmaceutiques solides a liberation prolongee
GB8521350D0 (en) * 1985-08-28 1985-10-02 Euro Celtique Sa Analgesic composition
EP0223431B1 (fr) * 1985-11-08 1992-04-29 Imperial Chemical Industries Plc Appareil et procédé pour former des particules extrudées
US4882156A (en) * 1985-12-20 1989-11-21 Warner Lambert Co. Confectionery delivery system for expectorants
US4882155A (en) * 1985-12-20 1989-11-21 Warner Lambert Co. Confectionery delivery system for antiarrhythmics
US4882153A (en) * 1985-12-20 1989-11-21 Warner Lambert Co. Confectionery delivery system for antitussives
US4882159A (en) * 1985-12-20 1989-11-21 Warner Lambert Co. Confectionery delivery system for appetite suppressants
US4882152A (en) * 1985-12-20 1989-11-21 Yang Robert K Confectionery delivery system for laxatives, vitamins and antacids
US4882157A (en) * 1985-12-20 1989-11-21 Yang Robert K Confectionery delivery system for anti-cholesterolemics
US4879108A (en) * 1985-12-20 1989-11-07 Warner-Lambert Company Confectionery delivery system for antipyretics
US4882151A (en) * 1985-12-20 1989-11-21 Warner Lambert Co. Confectionery delivery system for antihistimines
US4778676A (en) * 1985-12-20 1988-10-18 Warner-Lambert Company Confectionery delivery system for actives
DE3689727T2 (de) 1985-12-27 1994-07-07 Showa Denko Kk Granulierungsverfahren für enzyme.
DE3602370A1 (de) 1986-01-27 1987-08-06 Chrubasik Sigrun Verwendung von analgetica durch inhalation
DE3602360A1 (de) 1986-01-27 1987-07-30 Krupp Polysius Ag Seitenkratzer fuer schuettguthalde
US4764378A (en) * 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
GB2186485B (en) * 1986-02-13 1988-09-07 Ethical Pharma Ltd Slow release formulation
US4994227A (en) * 1986-03-10 1991-02-19 American Cyanamid Company Method for the preparation of sustained released bolus formulation
DE3610878A1 (de) 1986-04-01 1987-10-08 Boehringer Ingelheim Kg Formlinge aus pellets
DE3612211A1 (de) † 1986-04-11 1987-10-15 Basf Ag Kontinuierliches verfahren zum tablettieren
DE3612212A1 (de) 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
US4820523A (en) 1986-04-15 1989-04-11 Warner-Lambert Company Pharmaceutical composition
GB8613689D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
GB8613688D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
ATE107857T1 (de) 1986-06-10 1994-07-15 Euro Celtique Sa Zusammensetzung mit kontrollierter freisetzung von dihydrocodein.
USRE33093E (en) 1986-06-16 1989-10-17 Johnson & Johnson Consumer Products, Inc. Bioadhesive extruded film for intra-oral drug delivery and process
DE3623193A1 (de) 1986-07-10 1988-01-14 Gruenenthal Gmbh Neue verbindungen, diese enthaltende arzneimittel und verfahren zu deren herstellung
JPH0816066B2 (ja) 1986-07-18 1996-02-21 エーザイ株式会社 持続性薬効製剤
US4970075A (en) * 1986-07-18 1990-11-13 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US4861598A (en) * 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US4760094A (en) 1986-10-21 1988-07-26 American Home Products Corporation (Del.) Spray dried acetaminophen
GB8626098D0 (en) 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
IE873172L (en) 1986-12-29 1988-06-29 Harvard College Continuous process for producing a comestible tablet
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
ZA882783B (en) 1987-06-10 1988-10-20 Warner-Lambert Company Process for preparing a pharmaceutical composition
DE3721721C1 (de) 1987-07-01 1988-06-09 Hoechst Ag Verfahren zur Umhuellung von Granulaten
GB8717168D0 (en) 1987-07-21 1987-08-26 Roussel Lab Ltd Controlled-release device
FR2618329B1 (fr) 1987-07-22 1997-03-28 Dow Corning Sa Procede de fabrication d'un anneau capable d'assurer la liberation d'un agent therapeutique, et anneau fabrique par ce procede
US5049394A (en) * 1987-09-11 1991-09-17 E. R. Squibb & Sons, Inc. Pharmaceutical composition containing high drug load and method for preparing same
US4959208A (en) * 1987-10-19 1990-09-25 Ppg Industries, Inc. Active agent delivery device
US5418154A (en) * 1987-11-17 1995-05-23 Brown University Research Foundation Method of preparing elongated seamless capsules containing biological material
SE463450B (sv) 1987-12-11 1990-11-26 Nemo Ivarson Anordning foer blandning, knaadning och extrudering av produkter framstaellda av vaetska och pulver
EP0327295A3 (fr) 1988-02-01 1989-09-06 F.H. FAULDING & CO. LTD. Forme de dosage de la tétracycline
US4842761A (en) * 1988-03-23 1989-06-27 International Flavors & Fragrances, Inc. Compositions and methods for controlled release of fragrance-bearing substances
DE3812567A1 (de) * 1988-04-15 1989-10-26 Basf Ag Verfahren zur herstellung pharmazeutischer mischungen
US5472710A (en) 1988-04-16 1995-12-05 Schwarz Pharma Ag Pharmaceutical preparation to be administered orally with controlled release of active substance and method for its manufacture
DE3812799A1 (de) 1988-04-16 1989-10-26 Sanol Arznei Schwarz Gmbh Oral zu verabreichende pharmazeutische zubereitung mit kontrollierter wirkstofffreisetzung und verfahren zu deren herstellung
JP2681373B2 (ja) * 1988-07-18 1997-11-26 塩野義製薬株式会社 徐放性製剤の製造法
DE3827061C1 (fr) 1988-08-10 1990-02-15 Deutsche Gelatine-Fabriken Stoess & Co Gmbh, 6930 Eberbach, De
US4925675A (en) * 1988-08-19 1990-05-15 Himedics, Inc. Erythromycin microencapsulated granules
GB8820327D0 (en) 1988-08-26 1988-09-28 May & Baker Ltd New compositions of matter
DE3830353A1 (de) * 1988-09-07 1990-03-15 Basf Ag Verfahren zur kontinuierlichen herstellung von festen pharmazeutischen formen
DE3830355A1 (de) 1988-09-07 1990-03-15 Basf Ag Verfahren zur herstellung von pharmazeutischen tabletten
FI894611A (fi) 1988-09-30 1990-03-31 May & Baker Ltd Granulaera farmaceutiska preparat.
US5178868A (en) * 1988-10-26 1993-01-12 Kabi Pharmacia Aktiebolaq Dosage form
AU645003B2 (en) 1988-11-08 1994-01-06 Takeda Chemical Industries Ltd. Sustained release preparations
JP2893191B2 (ja) * 1988-11-08 1999-05-17 武田薬品工業株式会社 放出制御性マトリックス剤
IL92343A0 (en) * 1988-12-20 1990-07-26 Gist Brocades Nv Granulate for multiparticulate controlled release oral compositions,their preparation and oral pharmaceutical compositions containing them
EP0376331A3 (fr) * 1988-12-29 1991-03-13 Asahi Kogaku Kogyo Kabushiki Kaisha Granules pour la délivrance à faible vitesse d'un médicament et leur procédé de fabrication
CA2007055A1 (fr) 1989-01-06 1990-07-06 Garth Boehm Forme posologique de theophylline
US5196203A (en) * 1989-01-06 1993-03-23 F. H. Faulding & Co. Limited Theophylline dosage form
US5202128A (en) * 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
CA2007181C (fr) 1989-01-06 1998-11-24 Angelo Mario Morella Compose pharmaceutique a liberation continue
US5330766A (en) * 1989-01-06 1994-07-19 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5165952A (en) 1989-01-18 1992-11-24 Becton, Dickinson And Company Anti-infective and antithrombogenic medical articles and method for their preparation
US5013306A (en) * 1989-01-18 1991-05-07 Becton, Dickinson And Company Anti-infective and antithrombogenic medical articles and method for their preparation
FR2642420B1 (fr) 1989-01-27 1991-09-06 Valpan Sa Labo Pharma Nouvelle forme galenique a liberation programmee contenant une association de sels ferreux, d'acide succinique et d'acide ascorbique
US5007790A (en) * 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
US5229148A (en) * 1989-04-19 1993-07-20 Wm. Wrigley Jr. Company Method of combining active ingredients with polyvinyl acetates
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US4967486A (en) * 1989-06-19 1990-11-06 Glatt Gmbh Microwave assisted fluidized bed processor
DK161743C (da) * 1989-07-03 1992-02-17 Niro Atomizer As Fremgangsmaade og apparat til agglomerering af et pulverformigt materiale
JPH03163030A (ja) 1989-08-28 1991-07-15 Arizona Technol Dev Corp アヘン剤活性を選択的に強化し、アヘン剤耐性と依存性を軽減するための組成物と方法
EP0418596A3 (en) * 1989-09-21 1991-10-23 American Cyanamid Company Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form
DK469989D0 (da) * 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
US5169645A (en) * 1989-10-31 1992-12-08 Duquesne University Of The Holy Ghost Directly compressible granules having improved flow properties
IL96311A (en) 1989-12-01 1995-05-26 Abbott Lab Medications with delayed release
DE4000571C1 (fr) 1990-01-10 1991-06-06 Herbert 7853 Steinen De Huettlin
US5296266A (en) 1990-02-22 1994-03-22 Seiko Epson Corporation Method of preparing microcapsule
EP0452145B1 (fr) 1990-04-12 1996-11-13 SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. Composition revêtue et son procédé de préparation
US5225199A (en) * 1990-04-24 1993-07-06 Teijin Limited Pharmaceutical plasters
IE65045B1 (en) 1990-04-28 1995-10-04 Takeda Chemical Industries Ltd Granulated preparations and method of producing the same
US5183690A (en) * 1990-06-25 1993-02-02 The United States Of America, As Represented By The Secretary Of Agriculture Starch encapsulation of biologically active agents by a continuous process
AU643528B2 (en) 1990-06-25 1993-11-18 Mitsubishi Shoji Foodtech Co., Ltd. Molasses-containing maltitol crystal and production thereof
HU208495B (en) 1990-06-27 1993-11-29 Alkaloida Vegyeszeti Gyar Process for producing retarde pharmaceutical compositions
FR2663818B1 (fr) 1990-06-29 1993-07-09 Rhone Poulenc Nutrition Animale Procede de preparation de granules de principes actifs par extrusion.
GB2246514B (en) 1990-08-01 1993-12-15 Scras Sustained release pharmaceutical compositions and the preparation of particles for use therein
US5035509A (en) * 1990-08-13 1991-07-30 Hpm Corporation Multi-channel extrusion screw with a zig-zag undercut barrier
ES2075403T3 (es) 1990-08-24 1995-10-01 Spirig Ag Pharmazeutische Prap Procedimiento para la fabricacion de pellets.
JP2875611B2 (ja) * 1990-08-29 1999-03-31 エーザイ株式会社 ケイ酸カルシウム含有外用剤
US5102668A (en) * 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
DE4031881C2 (de) 1990-10-08 1994-02-24 Sanol Arznei Schwarz Gmbh Lösungsmittelfreie, oral zu verabreichende pharmazeutische Zubereitung mit verzögerter Wirkstoffreisetzung und Verfahren zu deren Herstellung
SE9003296L (sv) * 1990-10-16 1992-04-17 Kabi Pharmacia Ab Foerfarande foer att formulera laekemedel
GB2248842A (en) 1990-10-16 1992-04-22 American Cyanamid Co Film-forming polymer compositions
US5271934A (en) * 1990-10-22 1993-12-21 Revlon Consumer Products Corporation Encapsulated antiperspirant salts and deodorant/antiperspirants
FR2670398B1 (fr) 1990-12-14 1995-02-17 Roquette Freres Composition pulverulente directement compressible et procede d'obtention.
JPH0622669B2 (ja) 1990-12-17 1994-03-30 不二パウダル株式会社 前押出式スクリュー型押出し造粒機
US5240400A (en) * 1990-12-17 1993-08-31 Fuji Paudal Kabushiki Kaisha Screw-type extrusion granulating apparatus, especially for producing very fine granules
US5403593A (en) 1991-03-04 1995-04-04 Sandoz Ltd. Melt granulated compositions for preparing sustained release dosage forms
US5273758A (en) * 1991-03-18 1993-12-28 Sandoz Ltd. Directly compressible polyethylene oxide vehicle for preparing therapeutic dosage forms
US5132142A (en) * 1991-03-19 1992-07-21 Glatt Gmbh Apparatus and method for producing pellets by layering power onto particles
IT1245891B (it) 1991-04-12 1994-10-25 Alfa Wassermann Spa Formulazioni farmaceutiche a rilascio controllato per uso orale gastroresistenti contenenti acidi biliari e loro sali.
WO1992018106A1 (fr) 1991-04-16 1992-10-29 Nippon Shinyaku Co., Ltd. Procede de production d'une dispersion solide
TW209174B (fr) * 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
US5380535A (en) 1991-05-28 1995-01-10 Geyer; Robert P. Chewable drug-delivery compositions and methods for preparing the same
DK116591D0 (da) * 1991-06-17 1991-06-17 Ferring Farma Lab Fremgangsmaade til fremstilling af suppositorier ved komprimering og suppositorier opnaaet ved fremgangsmaaden
DE4120760A1 (de) * 1991-06-24 1993-03-04 3 M Medica Gmbh Traegersysteme fuer arzneimittel
US5330768A (en) * 1991-07-05 1994-07-19 Massachusetts Institute Of Technology Controlled drug delivery using polymer/pluronic blends
IT1251153B (it) 1991-08-06 1995-05-04 Vectorpharma Int Composizioni farmaceutiche solide per somministrazione orale aventi proungata residenza gastrica
DE4127665A1 (de) 1991-08-22 1993-02-25 Beiersdorf Ag Galenische matrix
US5340581A (en) 1991-08-23 1994-08-23 Gillette Canada, Inc. Sustained-release matrices for dental application
CA2077637C (fr) 1991-09-06 2007-01-09 Robert B. Raffa Compositions a base de tramadol ainsi que de codeine, d'oxycodone ou d'hydrocodone; leur utilisation
KR100243956B1 (ko) * 1991-09-06 2000-03-02 랄프 알. 팔로 트라마돌 물질 및 아세트아미노펜을 포함하는 통증 치료용 약제학적 조성물
US5215758A (en) 1991-09-11 1993-06-01 Euroceltique, S.A. Controlled release matrix suppository for pharmaceuticals
GB9121204D0 (en) 1991-10-04 1991-11-20 Euro Celtique Sa Medicament
US5288502A (en) * 1991-10-16 1994-02-22 The University Of Texas System Preparation and uses of multi-phase microspheres
WO1993007859A1 (fr) * 1991-10-23 1993-04-29 Warner-Lambert Company Nouveaux granules pharmaceutiques et procede de preparation
AU661723B2 (en) 1991-10-30 1995-08-03 Mcneilab, Inc. Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug
US5162117A (en) * 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition
DE4138513A1 (de) 1991-11-23 1993-05-27 Basf Ag Feste pharmazeutische retardform
US5266331A (en) † 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
DK0615438T3 (da) 1991-12-05 1996-11-11 Mallinckrodt Veterinary Inc En carbohydratglasmatrix til langvarig frigivelse af et terapeutisk middel
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5478577A (en) 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
GB2284760B (en) 1993-11-23 1998-06-24 Euro Celtique Sa A method of preparing pharmaceutical compositions by melt pelletisation
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
GB2281204A (en) 1993-07-27 1995-03-01 Euro Celtique Sa Sustained release morphine compositions
US5167964A (en) * 1992-02-14 1992-12-01 Warner-Lambert Company Semi-enteric drug delivery systems and methods for preparing same
DE69311394T2 (de) * 1992-02-20 1997-10-30 Euro Celtique Sa Arzneimittel verzögerter Wirkstoffabgabe
GB9203689D0 (en) * 1992-02-20 1992-04-08 Euro Celtique Sa Pharmaceutical composition
WO1993019739A1 (fr) * 1992-03-30 1993-10-14 Alza Corporation Suspensions visqueuses de particules de medicament a liberation regulee
US5262172A (en) * 1992-06-19 1993-11-16 Digestive Care Inc. Compositions of gastric acid-resistant microspheres containing buffered bile acids
US5234697A (en) * 1992-06-22 1993-08-10 Digestive Care Inc. Compositions of gastric acid-resistant microspheres containing salts of bile acids
US5429825A (en) 1992-06-26 1995-07-04 Mcneil-Ppc, Inc. Rotomelt granulation
US5350584A (en) 1992-06-26 1994-09-27 Merck & Co., Inc. Spheronization process using charged resins
DE4227385A1 (de) 1992-08-19 1994-02-24 Kali Chemie Pharma Gmbh Pankreatinmikropellets
JP2616252B2 (ja) 1992-10-16 1997-06-04 日本新薬株式会社 ワックスマトリックスの製法
DE4236408A1 (de) 1992-10-28 1994-05-05 Siemens Ag Schaltbare Dämpfungsvorrichtung
DE4236752A1 (de) 1992-10-30 1994-05-05 Asta Medica Ag Kombinationspräparat aus Flupirtin und Morphin zur Behandlung von Schmerzen und zur Vermeidung der Morphin-Abhängigkeit
IL109460A (en) 1993-05-10 1998-03-10 Euro Celtique Sa Controlled release formulation comprising tramadol
IT1265074B1 (it) 1993-05-18 1996-10-30 Istituto Biochimico Italiano Composizione farmaceutica a lento rilascio contenente come sostanza attiva un acido biliare
IL109944A (en) 1993-07-01 1998-12-06 Euro Celtique Sa Continuous release dosage form containing morphine and a method of preparing such sustained release unit dosage forms
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
DE4325465B4 (de) * 1993-07-29 2004-03-04 Zenz, Michael, Prof. Dr.med. Orales pharmazeutisches Präparat für die Schmerztherapie
DE4329794C2 (de) 1993-09-03 1997-09-18 Gruenenthal Gmbh Tramadolsalz enthaltende Arzneimittel mit verzögerter Wirkstofffreisetzung
EP2036558A3 (fr) † 1993-10-07 2010-04-28 Euro-Celtique S.A. Compositions d'opioides pour administration orale ayant un effet prolongé
US5476528A (en) 1993-12-20 1995-12-19 Tennessee Valley Authority System for improving material release profiles
JP3224931B2 (ja) 1994-01-12 2001-11-05 株式会社日本製鋼所 二軸混練押出機
US5395626A (en) 1994-03-23 1995-03-07 Ortho Pharmaceutical Corporation Multilayered controlled release pharmaceutical dosage form
DE4413350A1 (de) † 1994-04-18 1995-10-19 Basf Ag Retard-Matrixpellets und Verfahren zu ihrer Herstellung
DE4418837A1 (de) 1994-05-30 1995-12-07 Bayer Ag Thermisches Granulierverfahren
US5567439A (en) 1994-06-14 1996-10-22 Fuisz Technologies Ltd. Delivery of controlled-release systems(s)
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US6706284B2 (en) * 2001-03-15 2004-03-16 Yamanouchi Pharmaceutical Co., Ltd. Bitterness-reduced oral pharmaceutical composition
ATE431738T1 (de) * 2001-08-06 2009-06-15 Euro Celtique Sa Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist

Also Published As

Publication number Publication date
AU705894B2 (en) 1999-06-03
IL129410A (en) 2003-06-24
DE69535445T2 (de) 2008-01-24
DE69535426D1 (de) 2007-04-26
DK1449531T3 (da) 2007-07-30
CA2204180C (fr) 2000-10-31
PT785775E (pt) 2004-04-30
EP1741426B1 (fr) 2008-06-04
US6706281B2 (en) 2004-03-16
IL115871A (en) 1999-08-17
EP1449531A2 (fr) 2004-08-25
US7510727B2 (en) 2009-03-31
JP3186064B2 (ja) 2001-07-11
ES2282757T3 (es) 2007-10-16
EP0785775A1 (fr) 1997-07-30
ES2214512T3 (es) 2004-09-16
JPH10508608A (ja) 1998-08-25
DK1348429T3 (da) 2010-04-19
IL142413A (en) 2004-02-19
TW425288B (en) 2001-03-11
EP2283816A1 (fr) 2011-02-16
DK1741426T3 (da) 2008-10-06
IL129410A0 (en) 2000-02-17
EP1449530B1 (fr) 2007-03-14
HK1069110A1 (en) 2005-05-13
EP1348429A2 (fr) 2003-10-01
US5958452A (en) 1999-09-28
EP1741426A2 (fr) 2007-01-10
US6261599B1 (en) 2001-07-17
DK1449530T3 (da) 2007-07-02
PT1449531E (pt) 2007-06-25
PT1348429E (pt) 2010-03-09
ES2308675T3 (es) 2008-12-01
EP1449531A3 (fr) 2004-09-22
IL159766A (en) 2006-06-11
DE69532415T3 (de) 2013-03-28
DE69532415D1 (de) 2004-02-12
DE69535767D1 (de) 2008-07-17
ES2338641T3 (es) 2010-05-11
PT1741426E (pt) 2008-09-01
EP0785775B2 (fr) 2012-12-05
DK0785775T3 (da) 2004-05-24
DE69535426T2 (de) 2007-12-06
ATE397441T1 (de) 2008-06-15
DE69535445D1 (de) 2007-05-10
IL159766A0 (en) 2004-06-20
EP0785775A4 (fr) 1998-08-19
EP1449531B1 (fr) 2007-03-28
PT1449530E (pt) 2007-06-04
EP0785775B1 (fr) 2004-01-07
ATE356616T1 (de) 2007-04-15
ES2282756T3 (es) 2007-10-16
US20030026839A1 (en) 2003-02-06
EP1449530A2 (fr) 2004-08-25
DE69532415T2 (de) 2004-12-30
EP1348429B1 (fr) 2009-12-23
US6335033B2 (en) 2002-01-01
US20050089568A1 (en) 2005-04-28
US20010033865A1 (en) 2001-10-25
ATE257375T1 (de) 2004-01-15
HUT77626A (hu) 1998-06-29
US5965161A (en) 1999-10-12
EP1348429A3 (fr) 2003-11-26
ATE452627T1 (de) 2010-01-15
US20040185096A1 (en) 2004-09-23
EP1488786A1 (fr) 2004-12-22
DK0785775T4 (da) 2013-01-21
US20040081694A1 (en) 2004-04-29
US20010036476A1 (en) 2001-11-01
WO1996014058A1 (fr) 1996-05-17
AU4157096A (en) 1996-05-31
EP1741426A3 (fr) 2007-02-28
HK1059887A1 (en) 2004-07-23
US20100172974A1 (en) 2010-07-08
HK1069109A1 (en) 2005-05-13
CA2204180A1 (fr) 1996-05-17
EP1449530A3 (fr) 2004-09-22
ATE357909T1 (de) 2007-04-15
KR100232945B1 (ko) 1999-12-01
US20090148517A1 (en) 2009-06-11
DE69536035D1 (de) 2010-02-04
IL115871A0 (en) 1996-01-31
US6743442B2 (en) 2004-06-01

Similar Documents

Publication Publication Date Title
ZA959367B (en) Melt-extrusion multiparticulates
AU569431B2 (en) Pharmaceutical composition containing phenindamine
DE69520882T2 (de) Arzneizubereitung enthaltend amoxycillin und kaliumclavunalat
DE69832816D1 (de) Orale pharmazeutische dosierungsform mit verlängerter wirkstofffreisetzung
IS1812B (is) Meðferðaefnasambönd, lyfjafræðilega hæf sölt og samsetningar sem innihalda efnasamböndin, ásamt notkun þeirra
AU1904197A (en) Matrix tablet allowing the prolonged release of the sodium salt of tianeptine after administration by the oral route
DE69509621D1 (de) Diarylheptanoidderivat und diese enthaltende pharmazeutische Zusammensetzung
ZA984585B (en) Use of a pharmaceutical composition in the treatment of taumatic arthritis in horses
FI962728A (fi) Lääkeyhdistelmä yksilöiden riippuvuutta opiaateista ehkäisevänä lääkkeenä
IL137496A0 (en) Dosage form and pharmaceutical kit for increasing the oral availablity of pharmaceutical agents